Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 3
1957 9
1958 10
1959 7
1960 12
1961 6
1962 4
1963 1
1966 5
1967 3
1968 3
1969 2
1971 2
1972 1
1973 7
1974 6
1975 1
1976 8
1977 5
1978 4
1979 9
1980 6
1981 4
1982 5
1983 11
1984 13
1985 7
1986 12
1987 8
1988 3
1989 9
1990 5
1991 9
1992 5
1993 6
1994 4
1995 1
1996 4
1997 5
1998 2
1999 10
2000 5
2001 10
2002 10
2003 10
2004 4
2005 13
2006 12
2007 23
2008 21
2009 34
2010 26
2011 25
2012 30
2013 40
2014 37
2015 48
2016 57
2017 50
2018 55
2019 46
2020 73
2021 69
2022 72
2023 72
2024 94

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,067 results

Results by year

Filters applied: . Clear all
Page 1
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.
Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, Ostberg JR, Aguilar B, Wagner JR, Paul JA, Starr R, Wong RA, Chen W, Shulkin N, Aftabizadeh M, Filippov A, Chaudhry A, Ressler JA, Kilpatrick J, Myers-McNamara P, Chen M, Wang LD, Rockne RC, Georges J, Portnow J, Barish ME, D'Apuzzo M, Banovich NE, Forman SJ, Badie B. Brown CE, et al. Among authors: chaudhry a. Nat Med. 2024 Apr;30(4):1001-1012. doi: 10.1038/s41591-024-02875-1. Epub 2024 Mar 7. Nat Med. 2024. PMID: 38454126 Free PMC article. Clinical Trial.
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ. Zayac AS, et al. Among authors: chaudhry a. Blood Adv. 2023 Nov 14;7(21):6381-6394. doi: 10.1182/bloodadvances.2023009731. Blood Adv. 2023. PMID: 37171397 Free PMC article.
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.
Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN, Macias A, Del Real MM, Dhapola G, Egelston C, Murad JP, Rosa R, Paul J, Chaudhry A, Martirosyan H, Gerdts E, Wagner JR, Stiller T, Tilakawardane D, Pal S, Martinez C, Reiter RE, Budde LE, D'Apuzzo M, Kuhn P, Pachter L, Forman SJ, Priceman SJ. Dorff TB, et al. Among authors: chaudhry a. Nat Med. 2024 Jun;30(6):1636-1644. doi: 10.1038/s41591-024-02979-8. Epub 2024 Jun 12. Nat Med. 2024. PMID: 38867077 Free PMC article. Clinical Trial.
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, Fiaschi N, Coetzee S, Wang F, Ullman E, Ahmed HS, Herlihy E, Lee K, Havel L, Potocky T, Ebstein S, Frleta D, Khatri A, Godin S, Hamon S, Brouwer-Visser J, Gorenc T, MacDonald D, Hermann A, Chaudhry A, Sirulnik A, Olson W, Lin J, Thurston G, Lowy I, Murphy AJ, Smith E, Jankovic V, Sleeman MA, Skokos D. Wei J, et al. Among authors: chaudhry a. Sci Transl Med. 2022 Nov 9;14(670):eabn1082. doi: 10.1126/scitranslmed.abn1082. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350988
Smith-specific regulatory T cells halt the progression of lupus nephritis.
Eggenhuizen PJ, Cheong RMY, Lo C, Chang J, Ng BH, Ting YT, Monk JA, Loh KL, Broury A, Tay ESV, Shen C, Zhong Y, Lim S, Chung JX, Kandane-Rathnayake R, Koelmeyer R, Hoi A, Chaudhry A, Manzanillo P, Snelgrove SL, Morand EF, Ooi JD. Eggenhuizen PJ, et al. Among authors: chaudhry a. Nat Commun. 2024 Feb 6;15(1):899. doi: 10.1038/s41467-024-45056-x. Nat Commun. 2024. PMID: 38321013 Free PMC article.
Fluoroquinolone-Induced Sweet Syndrome: A Case Report.
Chaudhry AR, Iftikhar I, Choudhry SA, Islam R, Islam H. Chaudhry AR, et al. Cureus. 2023 Mar 31;15(3):e36952. doi: 10.7759/cureus.36952. eCollection 2023 Mar. Cureus. 2023. PMID: 37143489 Free PMC article.
Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy.
Farzeen Z, Khan RRM, Chaudhry AR, Pervaiz M, Saeed Z, Rasheed S, Shehzad B, Adnan A, Summer M. Farzeen Z, et al. Among authors: chaudhry ar. J Oncol Pharm Pract. 2024 Dec;30(8):1411-1431. doi: 10.1177/10781552241265058. Epub 2024 Jul 26. J Oncol Pharm Pract. 2024. PMID: 39056234 Review.
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.
Kim TM, Taszner M, Novelli S, Cho SG, Villasboas JC, Merli M, Jiménez-Ubieto A, Tessoulin B, Poon LM, Tucker D, Walewski J, Yi S, Song Y, Chong G, Bachy E, Guidez S, Alonso A, Jagadeesh D, Zhang W, Magnano L, Iskierka-Jażdżewska E, Tani M, Shen B, Uppala A, Zhu M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Luminari S; ELM-2 Investigators. Kim TM, et al. Among authors: chaudhry a. Ann Oncol. 2024 Nov;35(11):1039-1047. doi: 10.1016/j.annonc.2024.08.2239. Epub 2024 Aug 13. Ann Oncol. 2024. PMID: 39147364 Free article. Clinical Trial.
1,067 results